Notably, no difference in CA9 and VEGF expression between LFD and HFD conditions was observed in subcutaneous tumors (Figure 7B), in line with our earlier finding demonstrating that an increase in GLUT1 and augmented levels of other glycolysis-associated genes are observable only in metastatic tumors but not in primary tumors in PCa patients (Figure 1A), and in bone tumors but not in subcutaneous tumors in mice (Figure 1B and 1C). This evidence concerns the gene CA9 and posterior cortical atrophy.